About Ceapro
Ceapro is a company based in Edmonton (Canada) founded in 1997.. Ceapro offers products and services including Macimorelin DX, Avenanthramides, Oat Beta Glucan, Pressurized Gas Expanded (PGX), and AIM Biologicals. Ceapro operates in a competitive market with competitors including Avidity Biosciences, Univercells, OmniActive, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter Edmonton, Canada
- Stage Public
-
Sectors
HealthcareAgriculture
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$670.32 K (USD), Grant
Aug 27, 2019
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ceapro
Ceapro offers a comprehensive portfolio of products and services, including Macimorelin DX, Avenanthramides, Oat Beta Glucan, Pressurized Gas Expanded (PGX), and AIM Biologicals. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Diagnostic tool for assessing growth hormone deficiency in patients.
Oat-derived ingredient for potential antioxidant and health benefits.
Fiber-based product supporting immune and cardiovascular health functions.
Expanded gas technology for drug delivery applications in treatments.
Biological agents in development for targeted therapeutic uses.
Experimental agent for potential oncology or endocrine applications.
Variant of macimorelin for growth hormone stimulation testing.
Unlock access to complete
Unlock access to complete
Funding Insights of Ceapro
- Total Funding Total Funding
- Total Rounds 7
- Last Round Grant — $670,315
-
First Round
First Round
(29 Dec 2005)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2019 | Amount | Grant - Ceapro | Valuation |
investors |
|
| Sep, 2016 | Amount | Grant - Ceapro | Valuation |
investors |
|
| Jul, 2016 | Amount | Post-IPO - Ceapro | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ceapro
Ceapro has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Great Canadian Centre for Interest and Research. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Content is created and shared on diverse topics.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ceapro
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ceapro
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ceapro Comparisons
Competitors of Ceapro
Ceapro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, OmniActive, Sutro Biopharma and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Nutritional supplements for multiple health ailments are developed.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ceapro
Frequently Asked Questions about Ceapro
When was Ceapro founded?
Ceapro was founded in 1997 and raised its 1st funding round 8 years after it was founded.
Where is Ceapro located?
Ceapro is headquartered in Edmonton, Canada. It is registered at Edmonton, Alberta, Canada.
Who is the current CEO of Ceapro?
Gilles Gagnon is the current CEO of Ceapro.
What does Ceapro do?
Developer of biopharmaceutical products and diagnostic tools. This company develops and commercializes a portfolio of pharmaceutical and diagnostic products, including those addressing unmet medical needs. A key product is an FDA and European Commission-approved oral test for diagnosing adult growth hormone deficiency. The company also develops therapeutic assets and proprietary extraction technology for active ingredients from renewable plant resources, used in cosmeceutical and potential nutraceuticalpharmaceutical applications.
Who are the top competitors of Ceapro?
Ceapro's top competitors include Sutro Biopharma, OmniActive and Avidity Biosciences.
What products or services does Ceapro offer?
Ceapro offers Macimorelin DX, Avenanthramides, Oat Beta Glucan, Pressurized Gas Expanded (PGX), and 3 more products and services.
Who are Ceapro's investors?
Ceapro has 1 investor. Key investors include Great Canadian Centre for Interest and Research.